412018-50-9

Usage

Uses

Used in Pharmaceutical Industry:
1-(2,6-Dichloropyridin-3-yl)ethanone is used as a building block for the synthesis of various pharmaceuticals. Its versatile nature allows it to be incorporated into the development of new drugs, contributing to the advancement of medicine.
Used in Agrochemical Industry:
1-(2,6-Dichloropyridin-3-yl)ethanone is also used as a building block for the synthesis of agrochemicals, playing a crucial role in the development of pesticides and other agricultural products that help improve crop yields and protect plants from pests.
Used in Chemical Industry:
1-(2,6-Dichloropyridin-3-yl)ethanone is utilized as an intermediate in the manufacture of dyes and other fine chemicals. Its reactivity and utility in organic synthesis make it a valuable component in the production of a wide range of chemical products.
Used in Organic Synthesis:
Due to its versatile nature, 1-(2,6-Dichloropyridin-3-yl)ethanone is widely used in organic synthesis for the preparation of various organic compounds. Its unique properties enable chemists to create new molecules with potential applications in various industries.

Upstream product

• 873936-98-2 Ro 4808591 
• 75-16-1 methylmagnesium bromide 
• 38496-18-3 2,6-dichloropyridine-3-carboxylic acid 
• 917-64-6 methyl magnesium iodide 
• 58584-83-1 2,6-dichloronicotinoyl chloride 

Downstream Products

• 1375708-67-0 1-(2,6-dichloro-pyridin-3-yl)-ethanol 
• 1256826-72-8 6-chloro-3-methyl-1H-pyrazolo[3,4-b]pyridine 
• 1315180-57-4 C₂₃H₂₁FN₄O₅S 
• 1315179-88-4 1-(5-amino-2-fluoro-4-(methylsulfonyl)phenyl)-7-(3,5-dimethylisoxazol-4-yl)-2-methyl-1,4-dihydro-4-oxo-1,8-naphthyridine 
• 1315180-41-6 C₂₅H₂₃F₃N₄O₄ 
• 1315180-32-5 C₁₅H₁₁Cl₃FN₃O 
• 1315179-89-5 1-(5-amino-4-chloro-2-fluorophenyl)-7-(3, 5-dimethylisoxazol-4-yl)-2-methyl-1, 4-dihydro-4-oxo-1, 8-naphthyridine 
• 1315179-87-3 1-(5-acetylamino-4-bromo-2-fluorophenyl)-7-(3, 5-dimethylisoxazol-4-yl)-2-methyl-1, 4-dihydro-4-oxo-1, 8-naphthyridine 
• 1315179-84-0 1-(2-aminobenzyl)-7-(3, 5-dimethylisoxazol-4-yl)-2-methyl-1, 4-dihydro-4-oxo-1, 8-naphthyridine 
• 1315179-82-8 2-(aminomethyl)-1-(2, 4-difluorophenyl)-7-(3, 5-dimethylisoxazol-4-yl)-1, 4-dihydro-4-oxo-1, 8-naphthyridine 
• 1315180-53-0 2-azidomethyl-1-(2, 4-difluorophenyl)-7-(3, 5-dimethylisoxazol-4-yl)-1, 4-dihydro-4-oxo-1, 8-naphthyridine 
• 1315179-81-7 1-(2, 4-difluorophenyl)-7-(3, 5-dimethylisoxazol-4-yl)-2-hydroxymethyl-1, 4-dihydro-4-oxo-1, 8-naphthyridine 
• 1315179-80-6 1-(2, 4-difluorophenyl)-7-(3, 5-dimethylisoxazol-4-yl)-2-methyl-1, 4-dihydro-4-oxo-1, 8-naphthyridine 
• 1315179-79-3 1-(5-amino-2, 4-difluorophenyl)-7-(3, 5-dimethylisoxazol-4-yl)-2-hydroxymethyl-1, 4-dihydro-4-oxo-1, 8-naphthyridine 

Relevant academic research and scientific papers

INDAZOLE AND AZAINDAZOLE COMPOUNDS AS IRAK-4 INHIBITORS

The present invention provides indazole and aza indazole compounds of formula (I) or (II) and pharmaceutically acceptable salts thereof, and their use to inhibit IRAK-4 and/or for the treatment of diseases or disorders induced by IRAK-4.

HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES

Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions in need of inhibition of heparan sulfate biosynthesis.

DIFLUOROMETHYLENE COMPOUND

The present invention relates to a compound having an URAT1 inhibitory activity, and to an URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition containing the compound. More specifically, the present invention relates to a compound represented by the formula (I): wherein R1 is -Q1-A1 or the like; R2 is a hydrogen atom, a halogen atom, a lower alkyl group or the like; W1, W2, W3 and W4 are each independently a nitrogen atom or a methine group optionally having substituents, or the like; X and Y are each a single bond, an oxygen atom or the like; Z is a hydroxyl group or COOR3 or the like.

RING-FUSED COMPOUND

The present invention relates to a compound that has URAT1 inhibitory action, and a URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition comprising the compound. More specifically, the present invention relates to a compound represented by Formula (I) below. [in the formula, R1 is -Q1-A1 and the like; ---- is a double bond or a single bond; when ---- is a double bond, W1 is a nitrogen atom or a group represented by the general formula: =C(Ra)-, and W2 is a nitrogen atom or a group represented by the general formula: =C(Rb) -; when ---- is a single bond, W1 is a group represented by the general formula: -C(Raa)(Rab)- or a group represented by the general formula: -(C=O) -, and W2 is a group represented by the general formula: C(Rba)(Rbb)-, a group represented by the general formula: - (C=O) - or a group represented by the general formula: -N(Rbc)-; W3, W4 and W5 are each independently a nitrogen atom or a methine group and the like that may have a substituent; X is a single bond, an oxygen atom and the like; Y is a single bond or (CRYiRYi')n; and Z is a hydroxyl group or COOR2 and the like.

Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases

The present invention relates to novel compounds of formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising said compounds, processes for making said compounds, and their use as medicaments for treatment and/or prevention of Aβ-related diseases.